Our product development programs target specific subsets of cancer, and we seek to simultaneously develop, with partners, companion diagnostics that direct our product candidates to the patients most likely to benefit from their use. We believe this approach to personalized medicine – to deliver the right drug to the right patient at the right time – represents the future of cancer therapy.
We have three product candidates in our development pipeline: CO-1686, an oral epidermal growth factor receptor (EGFR), covalent inhibitor currently in Phase II development for the treatment of non-small cell lung cancer (NSCLC), in patients with initial activating EGFR mutations as well as the T790M dominant resistance mutation; rucaparib, an oral, small molecule poly (ADP-ribose) polymerase (PARP) inhibitor currently in Phase II and Phase III development for the treatment of platinum sensitive, relapsed ovarian cancer as well as Phase II development for pancreatic cancer; and our third product candidate, lucitanib, currently commencing Phase II development for the treatment of breast and lung cancers, is an oral, potent tyrosine kinase inhibitor which targets fibroblast growth factor receptors (FGFR)1-2, vascular endothelial growth factor receptors (VEGFR)1-3, and platelet-derived growth factor (PDGF) receptors alpha and beta.
We have global rights for CO-1686, rucaparib, and lucitanib.
For each of our clinical development programs, we are collaborating or intend to collaborate with leading developers of companion diagnostics in support of our drug development efforts. Through these collaborations, we have flexibility to choose the most appropriate technology for each program, and the expertise to gain regulatory approvals and support global commercialization that will parallel our own regulatory and commercialization paths.